EQL Pharma CEO sells shares to finance capital gains tax from option redemption

EQL Pharma CEO Axel Schörling has recently sold shares for approximately SEK 1.2 million to finance capital gains tax that arose upon redemption of the option program in September 2025.

Axel Schörling has sold 24,066 shares and holds 389,892 shares in EQL Pharma after the sale. The sale corresponded to 5.8% of Schörling's total holdings.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

Bifogade filer

PDF